<DOC>
	<DOCNO>NCT01743300</DOCNO>
	<brief_summary>In prospective pharmacokinetic investigate follow topic : - The influence grapefruit juice orange juice steady-state pharmacokinetics sunitinib cancer patient - The influence sunitinib pharmacokinetics midazolam cancer patient - The relationship Cytochrome-P450-3A4 ( CYP3A4 ) phenotype , assess use midazolam clearance test , steady-state pharmacokinetics sunitinib cancer patient - The effect grapefruit juice orange juice CYP3A4 metabolism</brief_summary>
	<brief_title>The Influence Phenotype , Grapefruit Juice Orange Juice Pharmacokinetics Sunitinib Cancer Patients</brief_title>
	<detailed_description>This prospective pharmacokinetic study two group 10 adult patient imatinib-resistant gastro-intestinal stromal cell tumor metastatic renal cell carcinoma treat sunitinib least one month . Patients treat recommended United States Food Drug Administration approve schedule oral sunitinib administer 25-50 mg per day 4 week , cycle six week . Four week treatment sunitinib , 25-50 mg per day follow 2 week period . In absence disease progression , administration sunitinib continue . Within one month start study , patient request refrain drinking grapefruit orange juice . The study take place 1 sunitinib treatment cycle 6 week ( 4 week treatment sunitinib ( week 1-4 ) 2 week period ( week 5 6 ) . The grapefruit juice orange juice administer 3 time per day 1 period 3 day 4th week treatment sunitinib . The first sunitinib ( total drug ) pharmacokinetics day perform steady-state sunitinib level reach , mean least 14 day start sunitinib 25 - 50 mg per day treatment ( week 3 treatment cycle sunitinib ) . On first pharmacokinetic day dose midazolam 7.5 mg give time sunitinib dose , observe effect sunitinib CYP3A4 capacity . Before second pharmacokinetic day ( day 28 sunitinib treatment ) patient drink 3 time day glass grapefruit juice orange juice three consecutive day.Patients assign either grapefruit juice orange juice arm . On second pharmacokinetic day patient use dose midazolam sam time sunitinib dose , observe effect grapefruit juice orange juice metabolic capacity pf CYP3A4 . The third pharmacokinetic day take place end week 6 treatment cycle , second week 2 week period . The patient receive single oral dose midazolam 7.5mg , follow midazolam pharmacokinetics determine base-line CYP3A phenotypic expression . Pharmacokinetic parameter base measurement plasma sample compare treatment period .</detailed_description>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Patients imatinibresistant gastrointestinal stromal cell tumor metastatic renal cell carcinoma treat sunitinib dose level 2550 mg sunitinib per day 4 week on/2 week schedule . Age least 18 year WHO performance status &lt; 2 . At least 4 week since last chemotherapy , hormonal , radiation therapy . A life expectancy least 12 week . Patients must adequate functional reserve define : hemoglobin &gt; 6.0 mmol/L , White Blood Count &gt; 3.0 x 109/L , neutrophil &gt; 1.5 x 109/L , platelet &gt; 100 x 109/L , creatinine clearance &gt; 60 mL/min , bilirubin within normal limit , Alanine transaminase aspartate transaminase &lt; 2.5 time upper limit normal ( unless due liver metastasis , &lt; 5 time upper limit normal . Written informed consent . Patients hematological malignancy Concurrent chemotherapy , immunotherapy , radiotherapy . Concurrent use substance know likely interfere pharmacokinetics sunitinib ( e.g. , ketoconazole , cyclosporine A ) . Use drug , herbal preparation and/or dietary supplement know influence expression CYP3A ( e.g. , phenytoin , rifampicin , St. John 's wort , garlic supplement , milk thistle ) within precede 2 week . Present clinical sign symptom brain and/or leptomeningeal metastasis confirm CT MRI brain scan . A patient brain and/or leptomeningeal metastasis may include he/she asymptomatic neurological examination receive corticosteroid therapy control symptom . Patients uncontrolled infection . Concurrent severe medical problem unrelated malignancy would limit full compliance study expose patient extreme risk . Patients preexist cardiac disease , include clinical congestive heart failure , cardiac arrhythmia require treatment , myocardial infarction within precede 3 month . Patients receive another investigational drug within 30 day 5 halflives prior entry study ( whichever longer ) . History allergic reaction compound chemically related sunitinib . Patients pregnant breastfeeding . Patients childbearing potential , practice adequate contraception . Patients unable ingest oral medication and/or know gastric empty disorder .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>sunitinib</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>phenotyping</keyword>
	<keyword>interaction</keyword>
</DOC>